Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-378 vs D745+D150 in Healthy Adults
NCT05741437Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-378 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the concentration-time curve from time zero to time t at 48 hours and Maximum plasma concentration at 48 hours. Started Apr 2023; status: completed.
02
Drugs
CKD-378
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05741437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741437.